Posted by Michael Wonder on 02 Aug 2022
Critics decry drug pricing provisions in Inflation Reduction Act, say they will stifle innovation
2 August 2022 - The push back against the prescription drug pricing provisions in the Inflation Reduction Act is relentless and hyperbolic.
It’s not uncommon to hear detractors suggest that the measures will “stifle innovation” and “devastate” the pharmaceutical industry. Certainly, imposing rebates on list prices of drugs that exceed an inflation index, restructuring Medicare Part D (outpatient), and requiring Medicare negotiations for certain drugs, will challenge the industry in unprecedented ways.
